Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase 1 clinical trial in 2022’s fourth quarter.

The decision to focus research on DMT for stroke treatment came after preclinical studies showed that DMT helps promote neurogenesis as well as structural and functional neural plasticity, which are key factors within the brain’s ability to make and reorganize synaptic connections after an injury.

In terms of progress, Algernon has completed its intravenous formulation (IVF), developed by the Centre for Human Drug Research (CHDR) and its affiliated pharmacy at the …

Full story available on Benzinga.com